fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

EBA Representatives discussed the development of the “Affordable Medicines” programme at the “Reimbursement 2025” forum

23/ 05/ 2025
  On 15 May 2025, the forum “Reimbursement 2025: Partnership for Sustainable Development” took place. Anna Bezruk, Manager of the Health Care Committee of the European Business Association, together with members of the Committee, had the opportunity to join the event. The forum brought together a wide range of participants, including representatives of the Ministry of Health of Ukraine, the National Health Service of Ukraine, pharmaceutical manufacturers who are members of the EBA, pharmacy chains, and other stakeholders. During the event, participants discussed the results of the reimbursement programme, plans for the inclusion of new medicinal products within existing nosologies based on the outcomes of health technology assessments and the inclusion of relevant INNs in the National Essential Medicines List, as well as prospects for expanding the programme to cover new therapeutic areas. EBA representatives noted the shared understanding of the need for a well-balanced approach to expanding the programme with new INNs, the development of a unified price calculation mechanism, and the exploration by public authorities of additional instruments for reimbursing innovative medicines at the outpatient level. In addition, the continued transition of INNs from centrally procured programmes to the reimbursement programme was recognised as an important direction of further development. The business community, as a partner of the state in implementing the reimbursement programme, emphasises the importance of open discussions about the future strategic development of the programme — taking into account both quantitative targets and a strengthened focus on addressing pressing public health issues with modern treatment methods. Moreover, timely engagement with manufacturers is expected to help prevent the emergence of unexpected barriers when introducing certain medicines into the programme. The European Business Association expresses its gratitude to the team at the National Health Service of Ukraine, which administers the “Affordable Medicines” reimbursement programme, for their ongoing work towards the programme’s development. The EBA also hopes for the continued joint efforts of the Ministry of Health and the NHSU to enhance patient access to effective medicines recommended by up-to-date clinical protocols. The EBA Health Care Committee additionally looks forward to maintaining an open and consistent dialogue with the business community and engaging Committee experts in discussions on the future development of the “Affordable Medicines” programme — one of the key mechanisms currently operating in Ukraine to improve public access to medicines funded by the state budget.
01/

On 15 May 2025, the forum “Reimbursement 2025: Partnership for Sustainable Development” took place. Anna Bezruk, Manager of the Health Care Committee of the European Business Association, together with members of the Committee, had the opportunity to join the event.

The forum brought together a wide range of participants, including representatives of the Ministry of Health of Ukraine, the National Health Service of Ukraine, pharmaceutical manufacturers who are members of the EBA, pharmacy chains, and other stakeholders.

During the event, participants discussed the results of the reimbursement programme, plans for the inclusion of new medicinal products within existing nosologies based on the outcomes of health technology assessments and the inclusion of relevant INNs in the National Essential Medicines List, as well as prospects for expanding the programme to cover new therapeutic areas.

EBA representatives noted the shared understanding of the need for a well-balanced approach to expanding the programme with new INNs, the development of a unified price calculation mechanism, and the exploration by public authorities of additional instruments for reimbursing innovative medicines at the outpatient level. In addition, the continued transition of INNs from centrally procured programmes to the reimbursement programme was recognised as an important direction of further development.

The business community, as a partner of the state in implementing the reimbursement programme, emphasises the importance of open discussions about the future strategic development of the programme — taking into account both quantitative targets and a strengthened focus on addressing pressing public health issues with modern treatment methods. Moreover, timely engagement with manufacturers is expected to help prevent the emergence of unexpected barriers when introducing certain medicines into the programme.

The European Business Association expresses its gratitude to the team at the National Health Service of Ukraine, which administers the “Affordable Medicines” reimbursement programme, for their ongoing work towards the programme’s development. The EBA also hopes for the continued joint efforts of the Ministry of Health and the NHSU to enhance patient access to effective medicines recommended by up-to-date clinical protocols.

The EBA Health Care Committee additionally looks forward to maintaining an open and consistent dialogue with the business community and engaging Committee experts in discussions on the future development of the “Affordable Medicines” programme — one of the key mechanisms currently operating in Ukraine to improve public access to medicines funded by the state budget.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: